Harvard Bioscience/$HBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Harvard Bioscience
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
Ticker
$HBIO
Sector
Primary listing
Employees
328
Headquarters
Website
HBIO Metrics
BasicAdvanced
$29m
-
-$12.80
1.45
-
Price and volume
Market cap
$29m
Beta
1.45
52-week high
$7.00
52-week low
$4.27
Average daily volume
63k
Financial strength
Current ratio
2.196
Quick ratio
1.123
Long term debt to equity
261.177
Total debt to equity
322.39
Interest coverage (TTM)
0.01%
Profitability
EBITDA (TTM)
7.443
Gross margin (TTM)
57.67%
Net profit margin (TTM)
-65.51%
Operating margin (TTM)
0.08%
Effective tax rate (TTM)
1.20%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
0.04%
Return on equity (TTM)
-147.13%
Valuation
Price to revenue (TTM)
0.327
Price to book
2.07
Price to tangible book (TTM)
-8.21
Price to free cash flow (TTM)
5.82
Free cash flow yield (TTM)
17.18%
Free cash flow per share (TTM)
1.096
Growth
Revenue change (TTM)
-8.06%
Earnings per share change (TTM)
349.24%
3-year revenue growth (CAGR)
-8.60%
10-year revenue growth (CAGR)
-2.25%
3-year earnings per share growth (CAGR)
77.21%
10-year earnings per share growth (CAGR)
8.43%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Harvard Bioscience stock?
Harvard Bioscience (HBIO) has a market cap of $29M as of May 01, 2026.
What is the P/E ratio for Harvard Bioscience stock?
The price to earnings (P/E) ratio for Harvard Bioscience (HBIO) stock is 0 as of May 01, 2026.
Does Harvard Bioscience stock pay dividends?
No, Harvard Bioscience (HBIO) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Harvard Bioscience dividend payment date?
Harvard Bioscience (HBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Harvard Bioscience?
Harvard Bioscience (HBIO) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.